Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.1598
Abstract: Importance The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective To evaluate the benefit of cetuximab added to concurrent chemoradiation… read more here.
Keywords: trial; treatment; cetuximab; cancer ... See more keywords
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.2915
Abstract: Importance Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment… read more here.
Keywords: trial; cetuximab; months months; rechallenge ... See more keywords
Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.3466
Abstract: Importance Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT. Objective… read more here.
Keywords: bevacizumab cetuximab; left sided; cetuximab; mortality ... See more keywords
Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31651
Abstract: Cetuximab combined with radiation therapy (RT) is an evidence‐based treatment for locally advanced head and neck squamous cell carcinoma (HNSCC); however, locoregional failure remains the primary cause of cancer‐related death in this disease. Intratumoral injection… read more here.
Keywords: cancer; cetuximab; head neck; egfr antisense ... See more keywords
Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30808
Abstract: Cetuximab is the single targeted therapy approved for the treatment of head and neck cancer (HNSCC). Predictive biomarkers have not been established and patient stratification based on molecular tumor profiles has not been possible. Since… read more here.
Keywords: response; treatment; cetuximab; basal subtype ... See more keywords
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32170
Abstract: An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET… read more here.
Keywords: cetuximab; hnscc; resistance cetuximab; activation ... See more keywords
Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34531
Abstract: Patients with metastatic colorectal cancer (mCRC) have poor long-term survival. Rechallenge with anti-epidermal growth factor receptor (anti-EGFR) based therapy has shown certain activity as late-line therapy. To further improve clinical outcomes, we evaluated the antitumor… read more here.
Keywords: cetuximab; metastatic colorectal; liposomal irinotecan; camrelizumab liposomal ... See more keywords
Radiotherapie mit Cetuximab oder Cisplatin beim Plattenepithelkarzinom der Kopf-Hals-Region – was ist zu bevorzugen?
Sign Up to like & getrecommendations! Published in 2019 at "Strahlentherapie und Onkologie"
DOI: 10.1007/s00066-019-01568-w
Abstract: Hintergrund Die Standardtherapie bei lokal fortgeschrittenen Plattenepithelkarzinomen der Kopf-Hals-Region („locally advanced head and neck squamous cell carcinoma“, LA-HNSCC) ist die primäre Operation, gefolgt von adjuvanter Radio(chemo)therapie, oder die definitive Radiotherapie mit konkomitanter Systemtherapie. Sowohl für… read more here.
Keywords: radiotherapie; die; cetuximab; oder ... See more keywords
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3458-7
Abstract: PurposeThe addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus… read more here.
Keywords: cetuximab; capecitabine; plus cetuximab; cancer ... See more keywords
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00753-7
Abstract: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets. With… read more here.
Keywords: kras nras; cetuximab; nras braf; cancer ... See more keywords
Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-0902-9
Abstract: Cetuximab is approved for treatment of squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is generally well tolerated, but does carry a black box warning for infusion reactions (IRs). Incidence of IR in… read more here.
Keywords: incidence; infusion reactions; assessment cetuximab; cetuximab ... See more keywords